PCV65 PHARMACOECONOMIC ANALYSIS OF 160MG VALSARTAN VERSUS LOSARTAN AND TELMISARTAN IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN THE MEXICAN HEALTH SECTOR
Abstract
Authors
JA Guzman F Carlos D Dector A Camacho F Fon C Castillejos